Fig. 4: Genomic and Clinical Properies of LPD Categories.
From: A novel stratification framework for predicting outcome in patients with prostate cancer
a OAS-LPD subgroups in The Cancer Genome Atlas Dataset (n = 333). Cancer samples were assigned to subgroups based on the most prominent signature as detected by OAS-LPD. The types of genetic alteration are shown for each gene (mutations, fusions, deletions and overexpression). Clinical parameters, including biochemical recurrence (BCR), are represented at the bottom, together with groups for iCluster, methylation, somatic copy number alteration (SVNA) and messenger RNA (mRNA).16 Comparison of the frequency of genetic alterations present in each subgroup are shown in Table 2. b–d Kaplan–Meier plots showing PSA-free survival outcomes for ETS-rearrangement positive cancers in LPD3 compared with all other ETS-positive cancers for the CancerMap, CamCap and TCGA datasets.
